Fidia SpA represents values of innovation, excellence, and commitment in its corporate philosophy. The company prioritizes research and development, aiming to bring advanced solutions to the medical and biotech sectors. Fidia SpA focuses on providing high-quality products and services, striving to meet the evolving demands of its customers. With a strong emphasis on sustainability and social responsibility, Fidia SpA contributes to a healthier future through its innovative pharmaceutical and biomedical technologies. As a leading company in its field, Fidia SpA consistently delivers value to its stakeholders while upholding its commitment to scientific progress and ethical business practices.

Fidia SpA is primarily present in various countries and regions globally. With its headquarters in Italy, Fidia SpA has established a strong presence within Europe. Additionally, it has expanded its reach to other regions, including North America, Latin America, Asia-Pacific, and the Middle East. Fidia SpA's international footprint allows the company to serve a diverse range of markets and customers, fostering growth and development on a global scale.

Fidia SpA has accomplished several significant milestones throughout its history. The company's commitment to excellence and innovation has led to remarkable achievements. Some notable milestones of Fidia SpA include successful development and commercialization of groundbreaking medical solutions, expansion into new markets, strategic collaborations with key industry players, and consistent growth in revenue and market share. Fidia SpA's dedication to research and development, along with its strong focus on customer satisfaction, has positioned the company as a leading player in the global healthcare industry.

Fidia SpA, a renowned Italian company, has a rich history and background. Established in 1946, Fidia SpA specializes in the development and production of innovative pharmaceuticals and healthcare technologies. With a strong commitment to research and development, the company has made significant contributions to the field of biotechnology. Fidia SpA has a diverse portfolio of products, including hyaluronic acid-based therapies for osteoarthritis and wound care. Over the years, Fidia SpA has expanded its presence globally, collaborating with international partners and maintaining a strong focus on patient well-being. As a reputable player in the healthcare industry, Fidia SpA continues to strive for excellence and deliver cutting-edge solutions in the pharmaceutical and biotechnology sectors.

The main competitors of Fidia SpA in the market are other companies operating in the pharmaceutical industry. These competitors include renowned players such as Novartis, Pfizer, Roche, and GlaxoSmithKline. Fidia SpA faces stiff competition in the global market as these companies specialize in the development and production of innovative medicines, medical devices, and innovative therapies. This competitive landscape challenges Fidia SpA to continuously focus on research and innovation, maintaining a strong market position, and offering unique value propositions for healthcare professionals and patients.

Fidia SpA operates primarily in the pharmaceutical and biotechnology industries.

Fidia SpA's business model revolves around the pharmaceutical industry. As a specialized research and development company, Fidia SpA focuses on the development and production of innovative drugs and medical devices. With a strong emphasis on biomaterials and hyaluronic acid-based therapies, Fidia SpA strives to improve patients' quality of life by addressing various medical conditions, including osteoarthritis and tissue regeneration. By leveraging its scientific expertise, cutting-edge technologies, and strategic partnerships, Fidia SpA remains committed to delivering high-quality, safe, and effective pharmaceutical solutions to patients globally.

Aktuálny KGV pre Fidia SpA sa nedá vypočítať.

Aktuálne nie je možné vypočítať KUV pre Fidia SpA.

AlleAktien kvalitatívne skóre pre Fidia SpA je 3/10.

Aktuálne nie je možné vypočítať obrat pre Fidia SpA.

Zisk momentálne nie je možné vypočítať pre Fidia SpA.

Fidia SpA aims to provide innovative solutions for the treatment of various diseases and injuries, focusing on the development and manufacturing of pharmaceuticals, medical devices, and cosmetic products. Through collaboration with international companies and research institutes, Fidia has a global influence on the pharmaceutical industry.

Fidia SpA vypláca dividendu vo výške 0 EUR rozdelenú do výplat počas roka.

Dividenda pre Fidia SpA sa aktuálne nedá vypočítať alebo spoločnosť nevypláca dividendu.

ISIN spoločnosti Fidia SpA je IT0001498481.

WKN spoločnosti Fidia SpA je 589983.

Ticker spoločnosti Fidia SpA je FDA.MI.

V posledných 12 mesiacoch spoločnosť Fidia SpA vyplatila dividendu vo výške 0,20 EUR . To zodpovedá dividendovému výnosu približne 106,67 %. Pre nadchádzajúcich 12 mesiacov bude pravdepodobne spoločnosť Fidia SpA vyplácať dividendu 0 EUR.

Súčasný výnos z dividend spoločnosti Fidia SpA je 106,67 %.

Fidia SpA vypláca dividendu každý štvrťrok. Tá je vyplácaná v mesiacoch jún, jún, jún, august.

Fidia SpA platil každý rok počas posledných 0 rokov dividendu.

Na nasledujúcich 12 mesiacov sa očakávajú dividendy vo výške 0 EUR. To zodpovedá dividendovému výnosu 0 %.

Fidia SpA je priradený sektoru 'Priemysel'.

Aby ste obdržali poslednú dividendu vo výške 0,2 EUR od Fidia SpA z dňa 5. 7. 2017, museli ste mať akciu v depozite pred ex-dňom 3. 7. 2017.

Posledná dividenda bola vyplatená 5. 7. 2017.

V roku 2023 boli od Fidia SpA 0 EUR vyplatené ako dividendy.

Dividendy spoločnosti Fidia SpA sú vyplácané v EUR.